A rapid HPLC method for the simultaneous determination of amiodarone and its major metabolite in rat plasma and tissues: A useful tool for pharmacokinetic studies

Journal of Chromatographic Science

Volumn 51, Issue 4, 2013, Pages 361-370

  Rodrigues, Márcio ^a,b,c   Alves, Gilberto ^b,c   Ferreira, Ana ^c   Queiroz, João ^c   Falcão, Amílcar ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DRUG DERIVATIVE;

ANIMAL; ARTICLE; BLOOD; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; METHODOLOGY; RAT; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TISSUE DISTRIBUTION; WISTAR RAT;

AMIODARONE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; LINEAR MODELS; LIQUID-LIQUID EXTRACTION; MALE; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84874767501     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/bms149     Document Type: Article

References (29)

1. Vassallo, P., Trohman, R.G.; Prescribing amiodarone: An evidencebased review of clinical indications; JAMA, (2007); 298: 1312-1322. (Pubitemid 47449439)
2. van Herendael, H., Dorian, P.; Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia; Vascular Health and Risk Management, (2010); 6: 465-472.
3. Freemantle, N., Lafuente-Lafuente, C., Mitchell, S., Eckert, L., Reynolds, M.; Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation; Europace, (2011); 13: 329-345.
4. US FDA. (2011) FDA Drug Safety Podcast for Healthcare Professionals: Severe liver injury associated with the use of dronedarone (marketed as Multaq). http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm240529.htm (accessed March 20, 2012).
5. Fukuchi, H., Nakashima, M., Araki, R., Komiya, N., Hayano, M., Yano, K., et al.; Effect of obesity on serum amiodarone concentration in Japanese patients: Population pharmacokinetic investigation by multiple trough screen analysis; Journal of Clinical Pharmacy and Therapeutics, (2009); 34: 329-336.
6. Wolkove, N., Baltzan, M.; Amiodarone pulmonary toxicity; Canadian Respiratory Journal, (2009); 16: 43-48.
7. Pé rez-Ruiz, T., Mart́nez-Lozano, C., Sanz, A., Bravo, E.; Development and validation of a capillary electrophoretic method for the determination of amiodarone and desethylamiodarone; Chromatographia, (2002); 56: 63-67. (Pubitemid 34765494)
8. Shayeganpour, A., Hamdy, D.A., Brocks, D.R.; Pharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodarone; Biopharmaceutics & Drug Disposition, (2008); 29: 159-166. (Pubitemid 351722160)
9. Roughead, E.E., Kalisch, L.M., Barratt, J.D., Gilbert, A.L.; Prevalence of potentially hazardous drug interactions amongst Australian veterans; British Journal of Clinical Pharmacology, (2010); 70: 252-257.
10. Trujillo, T.C., Nolan, P.E.; Antiarrhythmic agents: Drug interactions of clinical significance; Drug Safety, (2000); 23: 509-532. (Pubitemid 32001513)
11. Lesko, L.J.; Pharmacokinetic drug interactions with amiodarone; Clinical Pharmacokinetics, (1989); 17: 130-140. (Pubitemid 19199637)
12. Marot, A., Morelle, J., Chouinard, V.A., Jadoul, M., Lambert, M., Demoulin, N.; Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: A case report and review of the literature; Acta Clinica Belgica, (2011); 66: 134-136.
13. Libersa, C.C., Brique, S.A., Motte, K.B., Caron, J.F., Guédon-Moreau, L.M., Humbert, L., et al.; Dramatic inhibition of amiodarone metabolism induced by grapefruit juice; British Journal of Clinical Pharmacology, (2000); 49: 373-378. (Pubitemid 30195281)
14. Zhi, J., Moore, R., Kanitra, L., Mulligan, T.E.; Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers; Journal of Clinical Pharmacology, (2003); 43: 428-435. (Pubitemid 36368785)
15. Elsherbiny, M.E., El-Kadi, A.O., Brocks, D.R.; The effect of betanaphthoflavone on the metabolism of amiodarone by hepatic and extra-hepatic microsomes; Toxicology Letters, (2010); 195: 147-154.
16. Plomp, T.A., Wiersinga, W.M., Van Rossum, J.M., Maes, R.A.; Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after oral administration; In Vivo, (1987); 1: 265-279. (Pubitemid 18079258)
17. Najjar, T.A.; Disposition of amiodarone in rats after single and multiple intraperitoneal doses; European Journal of Drug Metabolism and Pharmacokinetics, (2001); 26: 65-69. (Pubitemid 32802397)
18. Elsherbiny, M.E., Brocks, D.R.; The effect of CYP1A induction on amiodarone disposition in the rat; Journal of Pharmceutical Sciences, (2010); 99: 539-548.
19. Al-Dhawailie, A.A.; High performance liquid chromatographic determination of amiodarone in plasma and tissues; Analytical Letters, (1995); 28: 2391-2400.
20. Jun, A.S., Brocks, D.R.; High-performance liquid chromatography assay of amiodarone in rat plasma; Journal of Pharmacy & Pharmaceutical Sciences, (2001); 4: 263-268. (Pubitemid 34305603)
21. Shayeganpour, A., Brocks, D.R.; Joint assay of desethylamiodarone and amiodarone in rat plasma by high performance liquid chromatography; Journal of Pharmacy & Pharmaceutical Sciences, (2003); 6: 160.
22. Moor, M.J., Wyss, P.A., Bickel, M.H.; New procedure for the highperformance liquid chromatographic determination of amiodarone and desethylamiodarone with solid-phase extraction of rat plasma and tissue samples; Journal of Chromatography, (1988); 431: 455-460.
23. Shayeganpour, A., Somayaji, V., Brocks, D.R.; A liquid chromatography-mass spectrometry assay method for simultaneous determination of amiodarone and desethylamiodarone in rat specimens; Biomedical Chromatography, (2007); 21: 284-290. (Pubitemid 46477470)
24. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes; Official Journal of the European Union, (2010); L276: 33-79.
25. Shah, V.P., Midha, K.K., Findlay, J.W., Hill, H.M., Hulse, J.D., McGilveray, I.J., et al.; Bioanalytical method validation-A revisit with a decade of progress; Pharmaceutical Research, (2000); 17: 1551-1557. (Pubitemid 32217566)
26. US DHHS, FDA, CDER. (2001) Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine. http://www.fda. gov/downloads/Drugs/ GuidanceComplianceRegulatorInformation/Guidances/ucm070107.pdf (accessed January 9, 2012).
27. EMA. (2011) Guideline on bioanalytical method validation, EMEA/CHMP/EWP/192217/2009, Committee for Medicinal Products for Human Use (CHMP). http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2011/08/WC500109686. pdf (accessed January 9, 2012).
28. Almeida, A.M., Castel-Branco, M.M., Falcão, A.C.; Linear regression for calibration lines revisited: Weighting schemes for bioanalytical methods; Journal of Chromatography B, (2002); 774: 215-222. (Pubitemid 34655493)
29. Mulder, J.E., Brien, J.F., Racz, W.J., Takahashi, T., Massey, T.E.; Mechanisms of amiodarone and desethylamiodarone cytotoxicity in nontransformed human peripheral lung epithelial cells; Journal of Pharmacology and Experimental Therapeutics, (2011); 336: 551-559.